Results 101 to 110 of about 20,461 (225)

Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real‐World National Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Evidence regarding the efficacy and safety of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in monogenic diabetes is limited. We evaluated real‐world metabolic, renal, and safety outcomes of SGLT2i therapy in adults with monogenic diabetes.
Estelle Audrain   +15 more
wiley   +1 more source

Nephrological perspectives on the underutilization of SGLT2is in heart failure and chronic kidney disease

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1490-1491, April 2025.
Özant Helvacı   +4 more
wiley   +1 more source

At the heart of home‐based care: multidisciplinary heart failure management in a quaternary centre's community programmes

open access: yesInternal Medicine Journal, EarlyView.
Abstract Background Heart failure (HF) is a frequent cause of hospital admissions, carrying a high risk of hospital readmission and mortality. Alfred Health General Medicine Hospital in the Home (GM‐HITH) and Hospital Admission Risk Program (HARP) offer multidisciplinary HF care to multimorbid patients in bed‐substitution and non‐admitted community ...
Elana Forbes   +8 more
wiley   +1 more source

Comparison of sarcopenia prevalence and prognostic features between HFrEF and HFpEF: a systematic review and meta-analysis

open access: yesFrontiers in Cardiovascular Medicine
BackgroundSarcopenia is closely associated with heart failure (HF); however, no prior meta-analysis has specifically addressed its relation with different ejection fraction phenotypes. This study investigated the prevalence of sarcopenia in patients with
Weizhu Xiong   +5 more
doaj   +1 more source

Refining Residual Ischemic Stroke Risk in Anticoagulated Atrial Fibrillation Using Index Outpatient LA Diameter: The CHA2DS2‐VALa Score

open access: yesJournal of Cardiovascular Electrophysiology, EarlyView.
In anticoagulated atrial fibrillation, residual ischemic stroke risk persists despite guideline‐directed therapy. In this single‐center cohort, an enlarged index outpatient left atrial diameter independently predicted stroke and improved risk stratification when added to CHA2DS2‐VA (CHA2DS2‐VALa), supporting a simple, clinically implementable ...
Sefa Erdi Ömür   +7 more
wiley   +1 more source

Synchronized diaphragmatic stimulation for the treatment of HFrEF—a review

open access: yesHeart Failure Reviews
Abstract The gap between maximally tolerated medical therapy and consideration for permanent mechanical circulatory support and/or cardiac transplant or palliative treatment of moderate to severe heart failure represents an underserved patient population. New therapies are evolving which may not only improve quality of life for these patients
L.R. Goldberg   +4 more
openaire   +2 more sources

NT‐proBNP as a Predictor of Atrial Fibrillation Recurrence After Cryoballoon, Radiofrequency and Pulsed‐Field Ablation

open access: yesPacing and Clinical Electrophysiology, EarlyView.
Central Illustration: In a study investigating AF recurrence after PVI with RFA, CBA, and PFA, elevated NT‐proBNP emerged as a strong predictor of recurrence within the first year, outperforming other clinical measures. Color‐coded recurrence‐free survival probability charts derived from these data are proposed to support individualized clinical ...
Johannes Bruss   +11 more
wiley   +1 more source

PFA Under Deep Sedation and Non‐Invasive Monitoring in Atrial Fibrillation Patients With Obstructive Sleep Apnea

open access: yesPacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Background Clinical data about pulsed field ablation (PFA) under deep sedation among patients with obstructive sleep apnea (OSA) are limited, while the optimal periprocedural monitoring is not established. We report our experience in PFA among patients with atrial fibrillation (AF) and OSA, using a continuous non‐invasive respiratory and ...
Dionyssios Leftheriotis   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy